SZSE Ticker: 002793

Luoxin Pharmaceuticals Group Stock Co., Ltd.

罗欣药业集团股份有限公司

罗欣药业

LUOXINPHARMACEUTICAL

Listing Date: 2016-04-15

Board: SME

Industry Classification: Manufacturing

The Genesis Index rose 1.06% in half a day! Auto sector strengthens Stock Channel Hexun.com

The Genesis Index rose 1.06% in half a day! Auto sector strengthens Stock Channel Hexun.com

The Genesis Index rose 1.06% in half a day! Auto sector strengthens

Hepatitis concept, new crown treatment, traditional Chinese medicine and other pharmaceutical stocks fell

Biomedical sector fell 0.91%, Miracle Pharmaceuticals rose 10.09% to top the list – yqqlm

Luoxin Pharmaceutical: The company has 6 varieties that will participate in the seventh batch of centralized procurement

Frog Pump Industry's IPO was rejected: the authenticity of revenue and performance is questioned

Frog Pump Industry's IPO was rejected: the authenticity of revenue and performance is questioned

Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com

Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022-

Biopharmaceutical sector rose 1.32%, Fudan Fuhua, Haipurui rose 10.04% to top the list – yqqlm

In the dividend season, 27 stocks are about to pay dividends – yqqlm

308 companies were surveyed by overseas institutions, and CTI Testing received the most attention

Biopharmaceutical sector rose 0.41%, Yaben Chemical rose 20.01% to top the list – yqqlm

2.389 billion yuan of main funds withdraw from the pharmaceutical and biological sector today_ Oriental Fortune Net

Luoxin Pharmaceutical and Ankon Technology, the world's first medical device Weitong Capsule will accelerate the commercialization

Luoxin Pharmaceutical and Ankon Technology, the world's first medical device Weitong Capsule will accelerate the commercialization

On the evening of May 9th, Shanghai and Shenzhen listed companies announced the latest express of major events_ Oriental Fortune Net

Frog Pump Industry's IPO was rejected: the authenticity of revenue and performance was questioned

Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer"

Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline

Want to see more data? Registered subscribers can see all the data.